Clinical Epidemiology & Biostatistics


Paul Moayyedi

BSc (Bristol), MB ChB (Bristol), PhD (Leeds), MRCP. FRCP

Richard Hunt-Astra Zeneca Chair in Gastroenterology

Professor, Department of Medicine

Associate Member, Dept of Clinical Epidemiology & Biostatistics

Member, Intestinal Disease Research Programme

905.525.9140 x 25679
moayyep@mcmaster.ca

Department of Medicine
Health Sciences Centre, Room 3N51D
McMaster University
1200 Main St. West
Hamilton, ON
L8N 3Z5

Office location: HSC-3N51D

Academic Interests

Dr. Moayyedi's research interests focus on the applications of H Pylori screening and treatment. He is interested in how H. pylori testing and treatment can be used to manage different patient groups. This includes the evaluation of the efficacy H. pylori test and treatment in uninvestigated dyspepsia and functional dyspepsia.

Dr. Moayyedi has conducted population based clinical trial research on the health economics and medical benefits H. pylori test and treat in the community. Additionally, he has published a series of systematic reviews on therapy for gastro-esophageal reflux disease, peptic ulcer disease and functional dyspepsia, performed as a Cochrane Editor for the Upper Gastrointestinal Disease Group. This work has led to involvement in a variety of guideline groups including the England and Wales National Institute of Clinical Excellence (NICE) evaluation of dyspepsia and that American Gastroenterology Association Technical Review of dyspepsia management.

Dr. Moayyedi also has a specific interested in health economics and medical decision modeling. He is currently developing an interest in the early detection of malignancy and GI cancer chemoprevention.

Selected Publications

  1. Moayyedi P, Delaney B, Vakil N, Forman D, Talley N. The efficacy of proton pump inhibitors in non-ulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 127: 1329-37, 2004.
  2. Jankowski J, Moayyedi P. Cost effectiveness of aspirin chemoprevention for Barrett’s esophagus. Journal of the National Cancer Institute 96: 885-887, 2004.
  3. Delaney B, Moayyedi P. Eradicating H. pylori does not increase symptoms of gastro-oesophageal reflux disease. BMJ 328: 1388-9, 2004.
  4. Moayyedi P, Duffy J, Delaney B. New approaches to enhance the accuracy of the diagnosis of reflux disease. Gut 53: 55-57, 2004.
  5. Sharma N, Donnellan C, Preston C, Delaney B, Duckett G, Moayyedi P. A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials. Gut 53: 58-65, 2004.
  6. Jankowski J, Provenzale D, Moayyedi P. Oesophageal adenocarcinoma arising from Barrett’s metaplasia has regional variations in the West. Gastroenterology 122: 588-90, 2002.
  7. Mason J, Feltbower R, Crocombe W, Duffett S, Axon ATR, Drummond, Moayyedi P. The effect of population H pylori screening and treatment on dyspepsia in the community: an economic analysis of a randomised controlled trial. Alimentary Pharmacology and Therapeutics 16: 559-568, 2002.
  8. Moayyedi P, Bardhan KD, Young L, Dixon MF, Brown L, Axon ATR. The effect if Helicobacter pylori eradication on reflux symptoms in gastro-esophageal reflux disease in patients: a randomised controlled trial. Gastroenterology 121: 1120-26, 2001.
  9. Moayyedi P, Soo S, Deeks J, Forman D, Mason J, Innes M, and Delaney B. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. British Medical Journal 321: 659-664, 2000.
  10. Moayyedi P, Feltbower R, J Brown, Mason S, Mason J, Nathan J, Richards IDG, Dowell AC, Axon ATR. The effect of population H pylori screening and treatment on dyspepsia and quality of life in the community: results of a randomised controlled trial. Lancet 355: 1665-1669, 2000.

Search for citations for Dr. Moayyedi on PubMed